Manu V Chakravarthy

US Patent:

20100261676, Oct 14, 2010

Filed:

Apr 12, 2010

Appl. No.:

12/758523

Inventors:

Clay F. Semenkovich - Ladue MO, US
Manu V. Chakravarthy - Scotch Plains NJ, US
John W. Turk - Eureka MO, US

Assignee:

WASHINGTON UNIVERSITY - St. Louis MO

International Classification:

A61K 31/685
C07F 9/06
A61P 1/16
G01N 33/48

US Classification:

514 78, 554 80, 436 63

Abstract:

Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARα)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARα-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals.

US Patent:

20230105984, Apr 6, 2023

Filed:

Dec 23, 2020

Appl. No.:

17/788474

Inventors:

Nadine Daou - Cambridge MA, US
Svetlana Marukian - Cambridge MA, US
- Cambridge MA, US
Svetlana Marukian - Watertown MA, US
Michael Hamill - Wellesley MA, US
Raffi Afeyan - Cambridge MA, US
Sean Carroll - Cambridge MA, US
Anthony Tramontin - Brooklyn NY, US
Manu Chakravarthy - Newton MA, US

International Classification:

A61K 31/198
A61K 31/194
A61K 31/221
A61K 31/46
A61K 31/4172
A61K 31/519
A61P 1/16

Abstract:

This disclosure provides combinations and methods for improving liver function, e.g., in a subject having a liver disease or disorder, or treating or preventing a liver disease or disorder, e.g., with hyperammonemia or muscle wasting in a subject.

US Patent:

20190388377, Dec 26, 2019

Filed:

Jun 19, 2019

Appl. No.:

16/446412

Inventors:

- Cambridge MA, US
Tony Tramontin - Brooklyn NY, US
Manu Chakravarthy - Newton MA, US
Raffi Afeyan - Boston MA, US
Svetlana Marukian - Watertown MA, US

International Classification:

A61K 31/198
A61K 38/05
A61P 1/16

Abstract:

This disclosure provides compositions and methods for improving liver function, e.g., in a subject having a liver disease or disorder, or treating a liver disease or disorder.